The failure of the Phase III IMblaze370 study evaluating the combination of Tecentriq (atezolizumab) and Cotellic (cobimetinib) was bad news for Swiss pharma giant Roche (ROG: SIX) and its Genentech biotech unit, but worse for US biotech Exelixis (Nasdaq: EXEL).
Tecentriq represents Roche’s biggest near-term hope as a challenger in the immuno-oncology (I-O) space, and it is partnering with Exelixis on Cotellic, a MEK inhibitor.
"We will continue to work with Genentech on the evaluation of cobimetinib’s potential in other tumor types, including in melanoma, in which there are two ongoing Phase III pivotal trials"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze